Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii84–ii86. doi: 10.1136/ard.61.suppl_2.ii84

Bone destruction in arthritis

E Gravallese
PMCID: PMC1766721  PMID: 12379632

Full Text

The Full Text of this article is available as a PDF (74.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. M., Maraskovsky E., Billingsley W. L., Dougall W. C., Tometsko M. E., Roux E. R., Teepe M. C., DuBose R. F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997 Nov 13;390(6656):175–179. doi: 10.1038/36593. [DOI] [PubMed] [Google Scholar]
  2. Bromley M., Woolley D. E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984 Sep;27(9):968–975. doi: 10.1002/art.1780270902. [DOI] [PubMed] [Google Scholar]
  3. Burgess T. L., Qian Y., Kaufman S., Ring B. D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W. J., Dunstan C. R. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999 May 3;145(3):527–538. doi: 10.1083/jcb.145.3.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fazzalari N. L., Kuliwaba J. S., Atkins G. J., Forwood M. R., Findlay D. M. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res. 2001 Jun;16(6):1015–1027. doi: 10.1359/jbmr.2001.16.6.1015. [DOI] [PubMed] [Google Scholar]
  5. Gori F., Hofbauer L. C., Dunstan C. R., Spelsberg T. C., Khosla S., Riggs B. L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000 Dec;141(12):4768–4776. doi: 10.1210/endo.141.12.7840. [DOI] [PubMed] [Google Scholar]
  6. Gravallese E. M., Harada Y., Wang J. T., Gorn A. H., Thornhill T. S., Goldring S. R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol. 1998 Apr;152(4):943–951. [PMC free article] [PubMed] [Google Scholar]
  7. Gravallese E. M., Manning C., Tsay A., Naito A., Pan C., Amento E., Goldring S. R. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000 Feb;43(2):250–258. doi: 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  8. Haynes D. R., Crotti T. N., Loric M., Bain G. I., Atkins G. J., Findlay D. M. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001 Jun;40(6):623–630. doi: 10.1093/rheumatology/40.6.623. [DOI] [PubMed] [Google Scholar]
  9. Horwood N. J., Kartsogiannis V., Quinn J. M., Romas E., Martin T. J., Gillespie M. T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999 Nov;265(1):144–150. doi: 10.1006/bbrc.1999.1623. [DOI] [PubMed] [Google Scholar]
  10. Hou Wu-Shiun, Li Weijie, Keyszer Gernot, Weber Ekkehard, Levy Roger, Klein Michael J., Gravallese Ellen M., Goldring Steven R., Brömme Dieter. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002 Mar;46(3):663–674. doi: 10.1002/art.10114. [DOI] [PubMed] [Google Scholar]
  11. Hsu H., Lacey D. L., Dunstan C. R., Solovyev I., Colombero A., Timms E., Tan H. L., Elliott G., Kelley M. J., Sarosi I. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540–3545. doi: 10.1073/pnas.96.7.3540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hummel K. M., Petrow P. K., Franz J. K., Müller-Ladner U., Aicher W. K., Gay R. E., Brömme D., Gay S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol. 1998 Oct;25(10):1887–1894. [PubMed] [Google Scholar]
  13. Itonaga I., Fujikawa Y., Sabokbar A., Murray D. W., Athanasou N. A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol. 2000 Sep;192(1):97–104. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH672>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  14. Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., Nishihara T., Takahashi N., Suda T. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol. 1999 Jul 1;163(1):434–442. [PubMed] [Google Scholar]
  15. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Komuro H., Olee T., Kühn K., Quach J., Brinson D. C., Shikhman A., Valbracht J., Creighton-Achermann L., Lotz M. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001 Dec;44(12):2768–2776. doi: 10.1002/1529-0131(200112)44:12<2768::aid-art464>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  17. Kong Y. Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999 Nov 18;402(6759):304–309. doi: 10.1038/46303. [DOI] [PubMed] [Google Scholar]
  18. Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A. J., Van G., Itie A. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999 Jan 28;397(6717):315–323. doi: 10.1038/16852. [DOI] [PubMed] [Google Scholar]
  19. Korganow A. S., Ji H., Mangialaio S., Duchatelle V., Pelanda R., Martin T., Degott C., Kikutani H., Rajewsky K., Pasquali J. L. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999 Apr;10(4):451–461. doi: 10.1016/s1074-7613(00)80045-x. [DOI] [PubMed] [Google Scholar]
  20. Korganow A. S., Weber J. C., Martin T. Modèles animaux et maladies auto-immunes. Rev Med Interne. 1999 Mar;20(3):283–286. doi: 10.1016/s0248-8663(99)83060-4. [DOI] [PubMed] [Google Scholar]
  21. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., Takahashi K., Furuya T., Ishiyama S., Kim K. J. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001 May;44(5):1003–1012. doi: 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  22. Kouskoff V., Korganow A. S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996 Nov 29;87(5):811–822. doi: 10.1016/s0092-8674(00)81989-3. [DOI] [PubMed] [Google Scholar]
  23. Lacey D. L., Tan H. L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000 Aug;157(2):435–448. doi: 10.1016/S0002-9440(10)64556-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998 Apr 17;93(2):165–176. doi: 10.1016/s0092-8674(00)81569-x. [DOI] [PubMed] [Google Scholar]
  25. Lam J., Nelson C. A., Ross F. P., Teitelbaum S. L., Fremont D. H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001 Oct;108(7):971–979. doi: 10.1172/JCI13890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Leisen J. C., Duncan H., Riddle J. M., Pitchford W. C. The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J Rheumatol. 1988 Jan;15(1):17–22. [PubMed] [Google Scholar]
  27. Lum L., Wong B. R., Josien R., Becherer J. D., Erdjument-Bromage H., Schlöndorff J., Tempst P., Choi Y., Blobel C. P. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 1999 May 7;274(19):13613–13618. doi: 10.1074/jbc.274.19.13613. [DOI] [PubMed] [Google Scholar]
  28. Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999 Nov 26;286(5445):1732–1735. doi: 10.1126/science.286.5445.1732. [DOI] [PubMed] [Google Scholar]
  29. Matsumoto Isao, Maccioni Mariana, Lee David M., Maurice Madelon, Simmons Barry, Brenner Michael, Mathis Diane, Benoist Christophe. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 2002 Mar 18;3(4):360–365. doi: 10.1038/ni772. [DOI] [PubMed] [Google Scholar]
  30. Min H., Morony S., Sarosi I., Dunstan C. R., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P. J., Lacey D. L. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000 Aug 21;192(4):463–474. doi: 10.1084/jem.192.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Miyamoto Noriki, Higuchi Yasumitsu, Mori Kouki, Ito Morihiro, Tsurudome Masato, Nishio Machiko, Yamada Hiroyuki, Sudo Akihiro, Kato Ko, Uchida Atsumasa. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol. 2002 Jan;2(1):25–38. doi: 10.1016/s1567-5769(01)00134-5. [DOI] [PubMed] [Google Scholar]
  32. Nagai M., Kyakumoto S., Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun. 2000 Mar 16;269(2):532–536. doi: 10.1006/bbrc.2000.2314. [DOI] [PubMed] [Google Scholar]
  33. Pettit A. R., Ji H., von Stechow D., Müller R., Goldring S. R., Choi Y., Benoist C., Gravallese E. M. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001 Nov;159(5):1689–1699. doi: 10.1016/S0002-9440(10)63016-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Redlich Kurt, Hayer Silvia, Maier Andrea, Dunstan Colin R., Tohidast-Akrad Makiyeh, Lang Susanne, Türk Birgit, Pietschmann Peter, Woloszczuk Wolfgang, Haralambous Silva. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002 Mar;46(3):785–792. doi: 10.1002/art.10097. [DOI] [PubMed] [Google Scholar]
  35. Romas E., Bakharevski O., Hards D. K., Kartsogiannis V., Quinn J. M., Ryan P. F., Martin T. J., Gillespie M. T. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000 Apr;43(4):821–826. doi: 10.1002/1529-0131(200004)43:4<821::AID-ANR12>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  36. Shalhoub V., Faust J., Boyle W. J., Dunstan C. R., Kelley M., Kaufman S., Scully S., Van G., Lacey D. L. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem. 1999 Feb 1;72(2):251–261. [PubMed] [Google Scholar]
  37. Shigeyama Y., Pap T., Kunzler P., Simmen B. R., Gay R. E., Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 2000 Nov;43(11):2523–2530. doi: 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  38. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–319. doi: 10.1016/s0092-8674(00)80209-3. [DOI] [PubMed] [Google Scholar]
  39. Suzuki Y., Nishikaku F., Nakatuka M., Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Rheumatol. 1998 Jun;25(6):1154–1160. [PubMed] [Google Scholar]
  40. Suzuki Y., Tsutsumi Y., Nakagawa M., Suzuki H., Matsushita K., Beppu M., Aoki H., Ichikawa Y., Mizushima Y. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology (Oxford) 2001 Jun;40(6):673–682. doi: 10.1093/rheumatology/40.6.673. [DOI] [PubMed] [Google Scholar]
  41. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., Koshihara Y., Oda H., Nakamura K., Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000 Feb;43(2):259–269. doi: 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  42. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., Nakagawa N., Yasuda H., Goto M., Tsuda E. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999 Nov;25(5):517–523. doi: 10.1016/s8756-3282(99)00210-0. [DOI] [PubMed] [Google Scholar]
  43. Wong B. R., Josien R., Lee S. Y., Sauter B., Li H. L., Steinman R. M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997 Dec 15;186(12):2075–2080. doi: 10.1084/jem.186.12.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wong B. R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett F. S., 3rd, Frankel W. N. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997 Oct 3;272(40):25190–25194. doi: 10.1074/jbc.272.40.25190. [DOI] [PubMed] [Google Scholar]
  45. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597–3602. doi: 10.1073/pnas.95.7.3597. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES